Le Lézard
Classified in: Health
Subject: SVY

Making a Case for Fairness: Leading Mental Health Experts Unveil National Survey Results that Support Making New Depression Medications Available to All Canadians


Mental health should be a priority for government and new depression medications should be available to everyone.

TORONTO, Sept. 23, 2019 /CNW/ - Leading mental health experts taking part in a panel discussion unveiled these and other findings at the annual conference, MentalHealthForAll, of the Canadian Mental Health Association (CMHA), held September 23?25 in Toronto, Ontario.

Nearly nine in ten Canadians polled in a national omnibus survey conducted by Nanos Research and commissioned by Canadians for Equitable Access to Depression Medication (CEADM) say that access to new depression medications for people living with depression is important or somewhat important. Eight in ten also said that it is important or somewhat important that new depression medications should be included on public drug plans.

"The survey indicates that a majority of Canadians believe that access to innovative depression medications is important and that access to mental health should be a priority for government decision makers. This denotes an openness among Canadians to engaging with mental health issues." says Mr. Nanos chair of Nanos Research, one of North America's premier research and strategy organizations.

The survey, which is accurate 19 times out of 20, indicates that:

However, despite such broad support by Canadians, access continues to be a major obstacle for those who need innovative depression medications to treat their illness but which are only available to people who have the luxury of a privately funded drug plan.

Brianne Moore, co-chair of CEADM, a 2019 Champion of Mental Health by the Canadian Alliance on Mental Illness and Mental Health, and one of the seven mental health experts on the CEADM panel, used her own experience to underscore this point. Ms. Moore, who has struggled with severe depression and anxiety for most of her life, knows first-hand what it's like to not be able to afford the depression medication she needed to manage her mental illness. "Every time I couldn't afford my medicine, I declined. This isn't right. Many Canadians like me struggle to access medication despite having a job. You shouldn't have to choose between buying food and paying for the medication you need to stay mentally healthy," said Ms. Moore.

The CEADM panelists unpacked the findings of the Nanos survey to underscore how a job lottery ? or access to a privately funded drug plan ? should not determine who can access the latest depression medications in order to recover from mental illness.

Joining Ms. Moore on the panel, which was facilitated by Patrick Dion, former Vice Chair of the Mental Health Commission of Canada, were Alexandra Apavaloae, senior research analyst with Nanos Research; Michael Landsberg, well-known radio host and founder of #sicknotweak; Colin Andersen, former Ontario deputy minister; and Dr. Javed Alloo, family physician with a special interest in mental health. Fardous Hosseiny, CMHA Interim National CEO, offered opening remarks.

They weighed in on the disparity that currently exists today, where Canadians who rely on their public drug plans to pay for medication can't access the latest depression medications available to people who have private drug plan coverage. Under the public drug plan system as it is operated today, government-sponsored medications only address mood symptoms, which is extremely inadequate as depression is a complex illness with 227 combinations of symptoms.

In light of the fact that 1 in 4 Canadians has depression severe enough to need treatment and that the World Health Organization has declared depression to be a global crisis in the 21st century, the experts also called for Canada's legislators and decision-makers to make equal access for all Canadians a national health care priority.

CEADM September 2019 Omnibus National Survey Results: http://bit.ly/2l0cZq3

These observations are based on an RDD dual frame (land- and cell-lines) hybrid telephone and online random survey of 1,000 Canadians, 18 years of age or older, between August 29th to September 4th, 2019 as part of an omnibus survey. The margin of error for this survey is ±3.1 percentage points, 19 times out of 20. This study was commissioned by Canadians for Equitable Access to Depression Medication (CEADM) and the research was conducted by Nanos Research.

SOURCE Canadians for Equitable Access to Depression Medication


These press releases may also interest you

at 13:26
In a bid to foster excellence and innovation in the healthcare industry, the esteemed Dr. Vidal Sheen proudly announces the launch of The Dr. Vidal Sheen Grant for Healthcare Students. With a robust focus on academic prowess, compassionate care, and...

at 13:17
Rexall is proud to unveil its first Pharmacist Care Walk-In Clinic in Barrie, Ontario on Friday, April 19. Located at 353 Duckworth Street, the clinic will offer personalized care to the community while providing immediate pharmacist treatment for...

at 13:13
Caring for communities extends beyond life-changing work in operating rooms and physician offices. Hartford HealthCare leadership today highlighted its corporate responsibility to environmental, social and economic sustainability in announcing its...

at 13:04
Concept Medical, a pioneer in innovative drug delivery technologies, proudly announces the commencement of its groundbreaking IDE clinical study, "MAGICAL-ISR" using MagicTouch ? Sirolimus drug coated balloon (DCB), for the management of in-stent...

at 12:30
The American College of Physicians (ACP) today released an update of its 2017 guideline with clinical recommendations for the use of newer pharmacological treatments of adults with Type 2 diabetes. The clinical guideline is based on the best...

at 12:10
Pieris Pharmaceuticals, Inc. today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The Company's...



News published on and distributed by: